Fáddáevttohusat
Fáddáevttohusat
- COVID-19 19
- Coronavirus infections
- SARS-CoV-2 19
- immunology
- COVID-19 (Disease) 18
- Coronavirus Infections 13
- Betacoronavirus 12
- Research 12
- Immunological aspects 10
- Development 9
- Vaccination 8
- prevention & control 8
- COVID-19 Vaccines 7
- Vaccines 7
- Drug Development 6
- Pandemics 6
- Pneumonia, Viral 5
- drug effects 5
- COVID-19 Pandemic, 2020- 4
- Treatment 4
- drug therapy 4
- virology 4
- Antibodies, Monoclonal 3
- Antibodies, Viral 3
- Antiviral agents 3
- Coronaviruses 3
- Monoclonal antibodies 3
- Seasons 3
- Therapeutic use 3
- Viral Vaccines 3
-
1
The COVID-19 outbreak an update on the SARS-CoV-2 virus /
Almmustuhtton 2020Viečča ollesdeavstta
Series
Elektrovnnalaš Jietna -
2
-
3
The immune system response to the SARS-COV-2 virus
Almmustuhtton 2020Viečča ollesdeavstta
Series
Elektrovnnalaš Jietna -
4
The paediatric response to the SARS-COV-2 virus and what we can learn from it
Almmustuhtton 2020Viečča ollesdeavstta
Series
Elektrovnnalaš Jietna -
5
SARS-COV-2 vaccine development where are we now? /
Almmustuhtton 2020Viečča ollesdeavstta
Series
Elektrovnnalaš Jietna -
6
The immune system response to the SARS-COV-2 virus an update /
Almmustuhtton 2020Viečča ollesdeavstta
Series
Elektrovnnalaš Jietna -
7
Development of an intranasal vaccine for SARS-CoV-2
Almmustuhtton 2020Viečča ollesdeavstta
Series
Elektrovnnalaš Jietna -
8
SARS-CoV-2 human monoclonal antibody therapy
Almmustuhtton 2020Viečča ollesdeavstta
Series
Elektrovnnalaš Jietna -
9
Convalescent plasma therapy as a treatment for COVID-19
Almmustuhtton 2020Viečča ollesdeavstta
Series
Elektrovnnalaš Jietna -
10
The development of SARS-CoV-2 vaccines
Almmustuhtton 2020Viečča ollesdeavstta
Series
Elektrovnnalaš Jietna -
11
The immune system response to the SARS-CoV-2 virus July 2020 update /
Almmustuhtton 2020Viečča ollesdeavstta
Series
Elektrovnnalaš Jietna -
12
Rheumatic diseases and COVID-19
Almmustuhtton 2020Viečča ollesdeavstta
Series
Elektrovnnalaš Jietna -
13
Presence and function of SARS-CoV-2-specific T-cells in recovered patients and healthy volunteers
Almmustuhtton 2020Viečča ollesdeavstta
Series
Elektrovnnalaš Jietna -
14
Potential long-term health effects of a SARS-CoV-2 infection
Almmustuhtton 2020Viečča ollesdeavstta
Series
Elektrovnnalaš Jietna -
15
Imperial College London's saRNA Vaccine - COVAC1
Almmustuhtton 2020Viečča ollesdeavstta
Series
Elektrovnnalaš Jietna -
16
Comparison of COVID-19 and seasonal HCoV pathologies and transfer to endemic state
Almmustuhtton 2021Viečča ollesdeavstta
Series
Elektrovnnalaš Jietna -
17
SARS-COV-2 human monoclonal antibody therapy update
Almmustuhtton 2021Viečča ollesdeavstta
Series
Elektrovnnalaš Jietna -
18
mRNA COVID-19 vaccine efficacy in recovered vs COVID-naive individuals
Almmustuhtton 2021Viečča ollesdeavstta
Series
Elektrovnnalaš Jietna -
19
SARS-CoV-2 monoclonal antibody testing in vivo
Almmustuhtton 2021Viečča ollesdeavstta
Series
Elektrovnnalaš Jietna